Research Article Open Access

A Randomized, Prospective Study to Compare the Efficacy and Tolerability of S-Amlodipine 2.5mg versus Racemic Amlodipine 5mg in Mild to Moderate Hypertension

Abstract

To compare the efficacy and tolerability of S-Amlodipine 2.5mg with racemic amlodipine 5mg in mild to moderate hypertension. 108 newly diagnosed patients with mild to moderate hypertension were enrolled. After randomization, 54 patients were assigned to receive S-Amlodipine 2.5mg and 54 patients to receive racemic amlodipine 5mg once daily for 12 weeks. Blood pressure, heart rate, ankle circumference and other adverse reactions were monitored every 2 weeks. Fifty patients in each group completed the study. The results were analyzed by Students t’ test. At 2&6 weeks, R amlodipine group showed a better efficacy in reducing both systolic and diastolic B.P (p=0.0001). At 12 weeks, both the study groups showed an equivalent efficacy in reducing the mean systolic (32.410.8; 29.6±9.0) and diastolic (13.45.9; 12.0±9.9) blood pressures (p=0.16 & 0.38). There was a significant increase in the mean ankle circumference in the Racemic amlodipine group compared to S-amlodipine group at 2, 6 & 12 weeks (p<0.05). There was no statistically significant change in renal & liver function tests. S-amlodipine 2.5 mg is found to be equivalent in efficacy and better in tolerability compared to Racemic amlodipine in mild to moderate hypertension at 12weeks.Racemic amlodipine proves to be more potent than s-amlodipine in reducing blood pressure.

Padmavathi T, J Ezhil Ramya, and B Meeanakshi

To read the full article Download Full Article | Visit Full Article